Nouscom announces appointment of Yen-Ching Chua as Vice President of Clinical Operations

We are thrilled to welcome Yen-Ching Chua as VP of Clinical Operations at Nouscom.

Yen-Ching is an experienced global clinical operations leader with over 20 years expertise in leading Pharmaceutical Development Operations including Quality Assurance and Pharmacovigilance. Yen-Ching joined Nouscom from Morphosys where she was the Global Head of Clinical Operations. In this position, she was a core member of the Research and Development Leadership Team leading the Global Clinical Operations teams dedicated to the quality execution of clinical trials. She developed and drove the implementation of organizational strategies to enable the global project teams in executing the clinical trials and real-word evidence (RWE) studies to advance the innovative investigational medicinal products to marketing authorization for patient access, leading to FDA approval of Monjuvi®. Prior to that Yen-Ching was the Global Head of Operations in the Chief Medical Office and Patient Safety organization in Novartis/Basel. Yen-Ching was also the Head of Clinical Operations at Sandoz Biopharmaceuticals (a Novartis Division) in Germany, where she was responsible for building a high-profile clinical operations team that accomplished multiple regulatory approvals, e.g. biosimilars for Rituximab, Enbrel, as well as Filgrastim.

Before that, Yen-Ching had roles of increasing responsibilities at Novartis in Basel, including Clinical Research Director in the Emerging Markets and Global Operations Manager in the Global Development Operations.

Yen-Ching trained in Biotechnology and Applied Sciences in Singapore and Australia, before she accepted her first roles in Clinical Research in Singapore with Quintiles and then with Novartis Asia Pacific.